Immunoprecise Intangible Assets vs Non Currrent Assets Other Analysis
IPA Stock | USD 1.13 0.04 3.42% |
Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Intangible Assets and its Non Currrent Assets Other accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
Intangible Assets vs Non Currrent Assets Other
Intangible Assets vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Intangible Assets account and Non Currrent Assets Other. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Immunoprecise Antibodies' Intangible Assets and Non Currrent Assets Other is -0.26. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Intangible Assets and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Immunoprecise Antibodies are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Intangible Assets i.e., Immunoprecise Antibodies' Intangible Assets and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | -0.26 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.The current year's Selling General Administrative is expected to grow to about 23.9 M, whereas Tax Provision is projected to grow to (1 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 11.0M | 11.6M | 13.3M | 14.0M | Total Revenue | 19.4M | 20.7M | 23.8M | 25.0M |
Immunoprecise Antibodies fundamental ratios Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Liab | 1.8M | 964K | 1.3M | 441K | 507.2K | 558.1K | |
Total Current Liabilities | 7.9M | 6.1M | 9.3M | 5.9M | 6.8M | 7.1M | |
Total Stockholder Equity | 15.1M | 56.9M | 75.3M | 57.8M | 66.5M | 69.8M | |
Property Plant And Equipment Net | 3.2M | 4.1M | 3.7M | 10.7M | 12.3M | 12.9M | |
Net Debt | 1.9M | (38.3M) | (27.4M) | (1.0M) | (911.7K) | (957.3K) | |
Retained Earnings | (22.5M) | (29.8M) | (46.5M) | (73.1M) | (65.8M) | (62.5M) | |
Accounts Payable | 1.8M | 3.0M | 4.8M | 3.4M | 3.9M | 4.1M | |
Cash | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Non Current Assets Total | 19.6M | 18.1M | 56.0M | 61.0M | 70.2M | 73.7M | |
Cash And Short Term Investments | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Net Receivables | 3.7M | 4.1M | 3.4M | 4.4M | 5.1M | 5.3M | |
Common Stock Shares Outstanding | 13.6M | 16.5M | 19.7M | 24.9M | 28.6M | 30.1M | |
Liabilities And Stockholders Equity | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Assets | 614.0K | 2.3M | 2.8M | 2.6M | 3.0M | 3.1M | |
Other Stockholder Equity | 3.5M | 6.6M | 7.3M | 10.8M | 9.7M | 9.2M | |
Total Liab | 12.2M | 10.0M | 18.2M | 20.0M | 23.0M | 24.2M | |
Total Current Assets | 7.7M | 48.9M | 37.5M | 16.8M | 19.3M | 20.3M | |
Non Current Liabilities Total | 4.2M | 4.0M | 8.9M | 14.1M | 16.2M | 17.0M | |
Non Currrent Assets Other | 85.1K | 79K | 82K | 86K | 77.4K | 73.5K | |
Short Long Term Debt Total | 4.5M | 3.5M | 2.5M | 7.3M | 8.4M | 8.8M | |
Property Plant And Equipment Gross | 3.1M | 4.1M | 9.4M | 17.1M | 19.6M | 20.6M | |
Accumulated Other Comprehensive Income | (300.2K) | (687K) | (2.5M) | 2.6M | 2.4M | 2.5M | |
Short Term Debt | 2.9M | 986K | 2.2M | 1.1M | 1.3M | 1.0M | |
Inventory | 818.6K | 1.2M | 1.6M | 2.1M | 2.4M | 2.5M | |
Current Deferred Revenue | 1.5M | 1.1M | 1.0M | 977K | 1.1M | 567.8K | |
Intangible Assets | 8.3M | 6.1M | 32.4M | 30.9M | 35.6M | 37.3M | |
Common Stock | 34.1M | 80.1M | 114.6M | 117.5M | 135.1M | 141.8M | |
Net Tangible Assets | (1.0M) | 43.1M | 23.2M | 7.7M | 8.9M | 12.5M | |
Net Invested Capital | 17.7M | 58.5M | 76.6M | 57.8M | 66.5M | 39.4M | |
Net Working Capital | (230.3K) | 42.8M | 28.2M | 10.9M | 12.5M | 13.7M | |
Property Plant Equipment | 3.1M | 4.0M | 3.3M | 10.4M | 12.0M | 12.5M | |
Other Liab | 2.6M | 1.5M | 8.6M | 7.9M | 9.1M | 5.1M | |
Other Assets | 287.6K | 163K | 476K | 437K | 393.3K | 373.6K | |
Good Will | 7.9M | 7.8M | 19.7M | 19.2M | 22.0M | 12.4M | |
Capital Lease Obligations | 1.9M | 1.9M | 1.2M | 7.3M | 8.4M | 8.8M | |
Long Term Investments | 118.9K | 111K | 142K | 115K | 132.3K | 122.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Transaction History View history of all your transactions and understand their impact on performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Revenue Per Share 0.939 | Quarterly Revenue Growth 0.203 | Return On Assets (0.11) | Return On Equity (0.26) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.